Lupus
6 months 1 week ago
Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session.
Measure Hydroxychloroquine levels! @RheumNow https://t.co/OnktkMSPR5
6 months 1 week ago
Lupus GPT - a chatbot which is much more relevant to Lupus - for patients and physician question etc. #EULAR2024 - Will be functional soon.
Looking forward to playing with this. #LLMs #ChatGPT
More to come. @RheumNow https://t.co/mGXG6A85Hx
6 months 1 week ago
Biomarkers in Lupus - Urine biomarkers @andreafava in #EULAR2024
We need these biomarkers to come in mainstream clinical practice if they work better than proteinuria. @RheumNow https://t.co/i7aeBx6qRR
6 months 1 week ago
@Lupusreference noted data suggests pulse IV methylprednisolone yields better outcomes for LN than adjustments of chronic oral steroids. #EULAR24 @RheumNow https://t.co/n93x036uIn
6 months 1 week ago
Precision medicine in Lupus is far from reality today. @Lupusreference @RheumNow #EULAR2024
6 months 1 week ago
Whats new in Lupus #EULAR2024 @Lupusreference lecture - many pearls.
Corticosteroids IV may be the way to go - referencing @AliDuarteMD team (better outcomes compared to oral steroids)
@RheumNow https://t.co/Fz1dZUVomF
6 months 1 week ago
Should we treat to target (T2T) for #SLE or just do SOC and gestalt (as most do in clinical practice)? @Lupusreference #EULAR24 @RheumNow
6 months 1 week ago
Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24
6 months 1 week ago
Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI
6 months 1 week ago
π Global disparities in steroid prescribing in #SLE
π HCQ assoc with decreased steroid use
π Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics
πSLE poster tour 15:30 TODAY
#EULAR2024
Abs #POS0013
@RheumNow https://t.co/7pL8kpeqOs